WO2020198481A1 - Compositions and methods for treating ocular disease - Google Patents

Compositions and methods for treating ocular disease Download PDF

Info

Publication number
WO2020198481A1
WO2020198481A1 PCT/US2020/024972 US2020024972W WO2020198481A1 WO 2020198481 A1 WO2020198481 A1 WO 2020198481A1 US 2020024972 W US2020024972 W US 2020024972W WO 2020198481 A1 WO2020198481 A1 WO 2020198481A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide
unit dose
salt
abu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/024972
Other languages
French (fr)
Inventor
Niranjan B. Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asclepix Therapeutics Inc
Original Assignee
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2021011727A priority Critical patent/MX2021011727A/en
Priority to EP20776493.7A priority patent/EP3946418A4/en
Priority to CA3134816A priority patent/CA3134816A1/en
Priority to JP2021557369A priority patent/JP7650074B2/en
Priority to KR1020217034683A priority patent/KR20210146352A/en
Priority to AU2020248438A priority patent/AU2020248438A1/en
Priority to US17/442,682 priority patent/US12540171B2/en
Priority to CN202080030026.4A priority patent/CN113710264A/en
Application filed by Asclepix Therapeutics Inc filed Critical Asclepix Therapeutics Inc
Priority to EA202192607A priority patent/EA202192607A1/en
Publication of WO2020198481A1 publication Critical patent/WO2020198481A1/en
Priority to IL286625A priority patent/IL286625A/en
Anticipated expiration legal-status Critical
Priority to ZA2021/07235A priority patent/ZA202107235B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Definitions

  • Diabetic macular edema (DME) and wet age-related macular degeneration (AMD) are the leading causes of blindness among adults. Progression of AMD leads to erosion of central vision, which is necessary for day-to-day activities such as reading, driving and identifying faces. While dry AMD leads to a gradual loss of vision, wet AMD leads to faster vision loss and is the most advanced form of the disease.
  • anti-VEGF drugs injectable vascular endothelial growth factor (anti-VEGF) inhibitors
  • anti-VEGF drugs include ranibizumab (LUCENTIS) and aflibercept (EYLEA).
  • LUCENTIS ranibizumab
  • EYLEA aflibercept
  • the ophthalmologist places anesthetic and antiseptic drops on the eye, then administers the anti-VEGF drug by injection into the vitreous (e.g., near the retina at the back of the eye).
  • the recommended frequency of these injections varies from every few weeks to every few months. Patients often require multiple doses over the course of a few months, and repeat treatments are needed for continued benefit.
  • the cost per treatment can be very high, around $2000 per injection in the U.S.
  • potential complications of intravitreal injection include infection (such as that caused by Streptococcus endophthalmitis ), retinal detachment, ocular hypertension, cataracts, inflammation, and others.
  • the invention provides methods and pharmaceutical compositions for treating ocular disease, including retinal diseases involving vascular permeability and/or inflammation.
  • the invention comprises administering about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to no more frequent than about once every two years.
  • the peptides form a clear gel upon intraocular injection, and provide a sustained release over an extended period, with a surprisingly small amount of active agent. Accordingly, the peptide can provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.
  • An exemplary collagen-IV-derived biomimetic peptide comprises, consists of, or consists essentially of the amino acid sequence LRRFSTAPFAFIDIMTVINF (SEQ ID NO: l).
  • the collagen IV-derived biomimetic peptides promote the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature.
  • the peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR).
  • VAGFR vascular endothelial growth factor receptor
  • HGFR hepatocyte growth factor receptor
  • IGFR insulin-like growth factor receptor
  • EGFR epidermal growth factor receptor
  • the peptide or salt thereof is administered to a patient having a condition selected from diabetic macular edema, retinal vein occlusion, AMD (e.g., wet AMD), or background diabetic retinopathy.
  • the patient has acute or chronic inflammation of the eye.
  • the patient has uveitis or an autoimmune or inflammatory condition that manifests in the eye.
  • about 1 mg or less of the collagen IV- derived biomimetic peptide, or salt thereof is administered by intraocular injection.
  • the collagen IV-derived biomimetic peptide, or salt thereof is administered at a dose of about 800 pg or less, or about 500 pg or less, or about 250 pg or less (e.g., from 50 to 150 pg) per intraocular inj ection.
  • the small amount of active agent provides a surprisingly long duration of action, which substantially reduces the frequency of required injections.
  • the peptide or salt thereof may be administered by intraocular injection no more frequently than about once every three months, or no more frequently than about once every four months, or no more frequently than about once every six months, or no more frequently than about once every eight months, or no more frequently than about once every year, or no more frequently than about once every 1.5 years, or no more frequently than about once every two years, or no more frequently than about once every three years.
  • the peptide is delivered without the use of advanced formulation technologies (e.g., particle encapsulation), such as nanoparticle or microparticle encapsulation, or liposome encapsulation. That is, the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution).
  • advanced formulation technologies e.g., particle encapsulation
  • the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution).
  • the physical properties of the peptide which are observed to form a clear gel in the vitreous, are sufficient for potent and long duration of action.
  • the peptide can be delivered for conditions (including macular edema, wet AMD) that are refractory or only partially-responsive to vascular endothelial growth factor (VEGF) blockade or inhibitor therapy.
  • conditions including macular edema, wet AMD
  • VEGF vascular endothelial growth factor
  • the invention provides pharmaceutical compositions suitable for intravitreal injection.
  • the pharmaceutical compositions comprise about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof (as disclosed herein) as a unit dose in a pre-filled syringe.
  • the unit dose may be about 700 pg or less of the peptide or salt thereof, or about 500 pg or less of the peptide or salt thereof, or about 250 pg or less of the peptide or salt thereof, or about 100 pg or less of the peptide or salt thereof.
  • An exemplary composition comprises a dose of from 50 to 150 pg of peptide (e.g., about
  • FIGURE 1A and FIGURE IB are graphs showing AXT107 inhibition of VEGF- induced vascular leakage by dosing of 100 pg of AXT107 (FIGURE 1A) and 500 pg of AXT107 (FIGURE IB) over 12 Months in Dutch-Belted Rabbits.
  • The“VEGF” bar indicates the no AXT107 control and is used to indicate the leakage that occurs in the absence of treatment with AXT107.
  • FIGURE 2 are graphs showing the amounts of AXT107 expressed as nanograms per gram (ng/g) that are present in the retina of Dutch-Belted Rabbits at various time points after intravitreal administration. AXT107 is found at significant levels in the retina 225, 271, and 315 days after a single injection.
  • FIGURE 3 is an image showing that AXT107 forms a gel upon injection in the rabbit eye.
  • the gel remains below the visual axis, and does not block either the visual axis or the optic nerve.
  • FIG. 4 shows images of the gel over 301 days for AXT107 doses of 100 pg, 250 pg, 500 pg, and 1000 pg after a single injection.
  • FIGURE 5 is a graph showing the release of AXT107 from gels at 100 pg, 250 pg, 500 pg, and 1000 pg overtime. Dashed lines show an estimate of the AXT107 levels through 361 days.
  • FIGURE 6 is an image showing AXT107 gel formation in human vitreous of different ages.
  • FIGURE 7 are images showing gels formed by AXT107 in the rabbit eye from AXT107 PK toxicology study of different doses from Dutch-Belted necropsy rabbits at 6 Months after administration. Arrows point to isolated AXT107 gels.
  • the invention provides methods and pharmaceutical compositions for treating ocular disease, including retinal diseases involving vascular permeability and/or inflammation.
  • the invention comprises administering about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to no more than about once every two years.
  • the peptides form a gel upon intraocular injection, and provide a sustained release over an extended period, with a surprisingly small amount of active agent. Accordingly, the peptide can provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.
  • the active agent is a collagen IV-derived biomimetic peptide that promotes the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature and providing anti-inflammatory action.
  • Ang2 Angiopoietin 2
  • the collagen IV-derived biomimetic peptides are derived from the a5 fibril of type IV collagen.
  • Exemplary peptides comprise, consist of, or consist essentially of the amino acid sequence LRRFSTAPFAFIDIMDVINF (SEQ ID NO: l), or derivatives thereof.
  • the peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR).
  • VEGFR vascular endothelial growth factor receptor
  • HGFR hepatocyte growth factor receptor
  • IGFR insulin-like growth factor receptor
  • EGFR epidermal growth factor receptor
  • Collagen IV-derived biomimetic peptides further include those described in US 9,056,923 and US 9,802,984, which are hereby incorporated by reference in their entireties.
  • peptides in accordance with the following disclosure include peptides comprising the amino acid sequence LRRFSTXPXXXXNINNVXNF (SEQ ID NO:2), where X is a standard amino acid or non-genetically encoded amino acid.
  • the peptide contains about 30 amino acids or less, or about 25 amino acids of less, or about 24 amino acids, or about 23 amino acids, or about 22 amino acids, or about 21 amino acids, or about 20 amino acids. In still other embodiments, one, two, three, four, or five amino acids of SEQ ID NO:2 are deleted. In some embodiments, the peptide comprises or consists of the amino acid sequence LRRFSTAPFAFINESiNVINF (SEQ ID NO:3). In some embodiments, the peptide comprises the amino acid sequence LRRFSTAPFAFIDINDVINF (SEQ ID NO: l), or derivative thereof.
  • Derivatives of the peptide of SEQ ID NO: l include peptides having from 1 to 5 amino acid substitutions, insertions, or deletions (e.g ., 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions collectively) with respect to SEQ ID NO: l, although in some embodiments the Asp at positions 13 and 16 are maintained.
  • the sequence DINDV is maintained in the derivative.
  • the peptide may have the amino acid sequence of LRRFSTXPXXXXDINDVXNF, where X is a standard amino acid or non-genetically encoded amino acid (SEQ ID NO:4).
  • the peptide contains about 30 amino acids or less, or about 25 amino acids of less, or about 24 amino acids, or about 23 amino acids, or about 22 amino acids, or about 21 amino acids, or about 20 amino acids. In still other embodiments, one, two, three, four, or five amino acids of SEQ ID NO:4 or SEQ ID NO: 1 are deleted.
  • amino acid substitutions are made at any position of a peptide of SEQ ID NO: l or 3, which can be independently selected from conservative or non conservative substitutions.
  • the peptide includes from 1 to 10 amino acids added to one or both termini (collectively).
  • the N- and/or C-termini may optionally be occupied by another chemical group (other than amine or carboxy, e.g., amide or thiol).
  • amino acid residues involved The 20 genetically encoded amino acids can be grouped into the following six standard amino acid groups:
  • “conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed within the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains one negative charge in the so modified polypeptide.
  • glycine and proline may be substituted for one another based on their ability to disrupt a-helices.
  • Some preferred conservative substitutions within the above six groups are exchanges within the following sub-groups: (i) Ala, Val, Leu and He; (ii) Ser and Thr; (iii) Asn and Gin; (iv) Lys and Arg; and (v) Tyr and Phe.
  • non-conservative substitutions are defined as exchanges of an amino acid by another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.
  • the biomimetic peptide or peptide agent is a peptide of from about 8 to about 30 amino acids, or from about 10 to about 20 amino acids, and has at least 4, at least 5, or at least 6 contiguous amino acids of SEQ ID NO: 1 or 3.
  • the peptide contains at least one, at least two, or at least three d-amino acids.
  • the peptide contains from one to about five ( e.g 1, 2, or 3) non- genetically encoded amino acids, which are optionally selected from 2-Aminobutyric acid (Abu), norleucine (Me), 4-chlorophenylalanine (4-ClPhe), and Allylglycine (AllylGly).
  • biomimetic peptides in accordance with the disclosure include:
  • FTNINNVTN (SEQ ID NO:26),
  • F SNINN V SNF (SEQ ID NO:28), FANINNVANF (SEQ ID NO:29),
  • FIDINDVINF SEQ ID NO:32
  • the biomimetic peptide forms a gel in human vitreous.
  • the peptide or salt thereof is administered to a patient having a condition selected from diabetic macular edema, retinal vein occlusion, AMD (e.g., wet AMD), or background diabetic retinopathy.
  • the patient has acute or chronic inflammation of the eye.
  • the patient has uveitis or an autoimmune or inflammatory condition that manifests in the eye.
  • the patient has macular edema.
  • Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell.
  • the causes of macular edema include chronic or uncontrolled diabetes type 2 (e.g., diabetic retinopathy), in which peripheral blood vessels including those of the retina leak fluid into the retina.
  • Other causes and/or associated disorders include age-related macular degeneration (AMD), chronic uveitis, atherosclerosis, high blood pressure and glaucoma.
  • AMD age-related macular degeneration
  • chronic uveitis chronic uveitis
  • atherosclerosis atherosclerosis
  • high blood pressure and glaucoma high blood pressure and glaucoma.
  • the patient has or is at risk of retinal vein occlusion, which can lead to severe damage to the retina and blindness, due to ischemia and edema.
  • the patient has AMD, which is optionally wet AMD or in some embodiments dry AMD.
  • the present invention in various embodiments provides for treatment of retinal disease with intravitreal injections of a collagen IV-derived biomimetic peptide, which only requires a small amount of active agent to be administered with infrequent injections.
  • an intravitreal injection is an injection into the eye, and in particular the vitreous which is a jelly-like fluid that fills the eye.
  • the health care provider injects medicine into the vitreous, near the retina at the back of the eye. The procedure often takes about 15 to 30 minutes.
  • the procedure generally involves placing drops in the eyes to dilate the pupils, numbing drops are placed in the eye, and drug is injected into the eye with a small needle.
  • Antibiotic drops may also be used to prevent infection. While the procedure is routine, it does not come without risks and potential complications. These include endophthalmitis, intraocular inflammation, retinal detachment, intraocular pressure elevation, ocular hemorrhage, in addition to systemic side effects. See, Falavarjani KG and Nguyen QD, Adverse events and complications associated with intravitreal injection of anti- VEGF agents: a review of literature. Eye 2013 Jul; 27(7): 787-794. Further, the procedure for administering conventional anti-VEGF drugs is costly and not convenient since frequent injections are generally required.
  • the collagen IV- derived biomimetic peptide, or salt thereof is administered by intraocular injection.
  • the unit dose of peptide is administered at the bottom of the eye, such as between 5:00 and 7:00, so that gel forms at the bottom.
  • the collagen IV- derived biomimetic peptide, or salt thereof is administered at a dose of from about 25 pg to about 1000 pg.
  • about 800 pg or less, or about 700 pg or less, or about 500 pg or less, or about 250 pg or less, or about 100 pg or less of the peptide or salt thereof is administered per intraocular injection.
  • the unit dose is greater than 1 mg, such as from 1 mg to about 2 mg.
  • the small amount of active agent provides a surprisingly long duration of action, which substantially reduces the frequency of required injections.
  • the peptide or salt thereof may be administered by intraocular injection no more frequently than about once every three months, or no more frequently than about once every four months, or no more frequently than about once every six months, or no more frequently than about once every eight months, or no more frequently than about once every year, or no more frequently than about once every 1.5 years, or no more frequently than about once every two years, or no more frequently than about once every three years.
  • the peptide is delivered without the use of advanced formulation technologies (e.g., particle encapsulation), such as nanoparticle or microparticle encapsulation, or liposome encapsulation. That is, the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution).
  • advanced formulation technologies e.g., particle encapsulation
  • the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution).
  • the physical properties of the peptide, which are observed to form a gel in the vitreous, are sufficient for potent and long duration of action.
  • about 10 pg to about 50 pg of the collagen IV-derived biomimetic peptide, or salt thereof is administered per intraocular injection, and at a frequency of about once per month or about once every other month.
  • about 25 pg of the peptide or salt thereof may be administered by intraocular injection about monthly.
  • about 50 pg to about 150 pg per intraocular injection is administered at a frequency of no more than about once every third month, or no more frequently than about once every fourth month, or no more frequently than about once every six months.
  • the peptide or salt thereof may be administered at about 50 pg and at a frequency of about once every three or four months.
  • the peptide or salt thereof is administered at about 100 pg to about 150 pg per injection, and at a frequency of about once every five to seven months, and optionally about once every six months. In some embodiments, the dose of 100 to 150 pg is administered about once every eight months or about once every nine months.
  • the amount of active agent delivered per injection is increased, providing unexpected durations of action.
  • the collagen IV-derived biomimetic peptide or salt thereof may be administered at about 150 pg to about 250 pg per intraocular injection, and at a frequency of no more than about once every six months.
  • the peptide or salt thereof may be administered no more frequently than about once every eight months.
  • the peptide or salt thereof is administered no more frequently than about once every ten months or about once every twelve months.
  • the peptide or salt thereof is administered at about 200 pg and at a frequency of about once every six to eight months.
  • the peptide or salt thereof is administered at about 250 pg and at a frequency of about once every six to twelve months.
  • the peptide or salt thereof is administered at from about 250 pg to about 1 mg per intraocular injection, and at a frequency of no more than about once every six months.
  • the peptide or salt thereof is administered at about 300 pg to about 700 pg per injection, or is administered at about 400 pg to about 700 pg per injection, or is administered at about 500 pg to about 700 pg per injection, or is administered at about 600 pg to about 700 pg per injection.
  • the peptide or salt thereof is administered at a frequency of about once every six to twelve months.
  • the peptide or salt thereof is administered about once every seven months, about once every eight months, about once every nine months, about once every ten months, about once every eleven months, or about once every twelve months, or about once every 18 months.
  • the peptide or salt thereof is administered at from about 700 pg to about 1 mg per intraocular injection, and at a frequency of no more than once every twelve months or no more than once every 15 months. In some embodiments, the peptide or salt thereof is administered at about 800 pg to about 1 mg per injection, or is administered at about 900 pg to about 1 mg per injection, or is administered at a frequency of once every twelve to eighteen months. In some embodiments, the peptide or salt thereof is administered about once every two years or about once every three years.
  • the peptide dosed as described above is the peptide consisting of SEQ ID NO: l (AXT107).
  • the patient will receive a plurality of doses, and in some embodiments, therapy can be continuous at the recommended frequency of injections for disease control or management. In some embodiments, therapy need not be continuous, where symptoms or disease has been substantially alleviated. In various embodiments, the patient receives at least two injections, or at least four injections, or at least six injections, or at least eight injections, or at least ten injections. In some embodiments, injections are provided in a regimen of from four to ten injections.
  • the collagen IV-derived peptide promotes the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature.
  • the peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR).
  • VEGFR vascular endothelial growth factor receptor
  • HGFR hepatocyte growth factor receptor
  • IGFR insulin-like growth factor receptor
  • EGFR epidermal growth factor receptor
  • the peptide can be delivered for conditions (including macular edema, wet AMD) that are refractory or only partially-responsive to vascular endothelial growth factor (VEGF) blockade or inhibitor therapy.
  • VEGF vascular endothelial growth factor
  • Pharmaceutical agents that block VEGF include aflibercept, bevacizumab, ranibizumab, and ramucirumab, and similar agents, which are administered to slow or block angiogenesis.
  • kinase inhibitors such as pazopanib, sorafenib, sunitinib, axitinib, ponatinib, lenvatinib, vandetanib, regorafenib, and cabozantinib.
  • Aflibercept is a biopharmaceutical drug for the treatment of wet macular degeneration (EYLEA).
  • Aflibercept is an inhibitor of VEGF, and is a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, that are fused to the Fc portion of the human IgGl immunoglobulin.
  • VEGF vascular endothelial growth factor
  • Aflibercept binds to VEGFs and acts like a“VEGF trap”, inhibiting the activity of the vascular endothelial growth factor subtypes VEGF -A and VEGF-B, as well as to placental growth factor (PGF).
  • PPF placental growth factor
  • Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels.
  • Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting VEGF-A.
  • Bevacizumab is administered for treating certain metastatic cancers, including colon cancer, lung cancers (e.g NSCLC), renal cancers, ovarian cancers, breast cancer, and glioblastoma. Bevacizumab can also be used for treatment of eye diseases, including AMD and diabetic retinopathy.
  • Ranibizumab (LUCENTIS) is a monoclonal antibody fragment (Fab), and is administered for treatment of wet AMD.
  • Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting VEGF A, similar to Bevacizumab.
  • the biomimetic peptide may be administered after unsuccessful VEGF blockade therapy, that is, where reductions in angiogenesis, lymphangiogenesis, and/or edema were not observed.
  • the peptide is administered as an alternative to VEGF blockade therapy.
  • the peptide is administered in combination with VEGF blockade therapy, either simultaneously with, before, or after a VEGF blockade regimen.
  • the peptide or salt thereof is administered after unsuccessful VEGF blockade or inhibitor therapy.
  • the patient has a condition that is refractory or only partially-responsive to VEGF blockade or inhibitor therapy.
  • the invention provides pharmaceutical compositions suitable for intravitreal injection.
  • the pharmaceutical compositions comprise about 1 pg to about 1 mg or about 25 pg to about 800 pg of a collagen IV-derived biomimetic peptide or salt thereof (as disclosed herein) as a unit dose in a pre-filled syringe.
  • the unit dose may be about 700 pg or less of the peptide or salt thereof, or about 500 pg or less of the peptide or salt thereof, or about 250 pg or less of the peptide or salt thereof, or about 100 pg or less of the peptide or salt thereof.
  • Exemplary unit doses include about 100 pg, about 250 pg, about 500 pg, and about 750 pg.
  • the composition has a unit dose of from about 10 pg to about 50 pg of the peptide or salt thereof. In other embodiments, the composition has a unit dose of from about 50 pg to about 150 pg (e.g., about 100 pg) of the peptide or salt thereof. In some embodiments, the composition has a unit dose of from about 150 pg to about 250 pg of the peptide or salt thereof.
  • the composition has a unit dose of from about 250 pg to about 700 pg, or about 300 pg to about 700 pg, or about 400 pg to about 700 pg, or about 500 pg to about 700 pg, or about 600 pg to about 700 pg of the peptide or salt thereof.
  • the pharmaceutical composition has a unit dose of from about 700 pg to about 1 mg, or from about 800 pg to about 1 mg, of the peptide or salt thereof. In some embodiments, the unit dose is about 1 mg. In some embodiments, the unit dose is greater than 1 mg, such as from about 1 mg to about 2 mg.
  • the unit dose volume (in accordance with the compositions and methods described herein) may be in the range of about 1 m ⁇ to about 1 mL, or from about 10 pL to about 0.5 mL, or from about 10 pL to about 250 pL, or from about 10 pL to about 50 pL.
  • the pharmaceutical composition comprises a unit volume of from about 25 pL to about 0.5 mL, or a unit volume of from about 25 pL to about 200 pL, or a unit volume of from about 25 pL to about 100 pL.
  • the unit volume is less than about 100 pL, or less than about 50 pL, or less than about 25 pL.
  • the volume is about 50 pL.
  • biomimetic peptides or peptide agents can be chemically synthesized and purified using well-known techniques, such as solid-phase synthesis. See US 9,051,349, which is hereby incorporated by reference in its entirety.
  • Peptides may be provided in the form of a pharmaceutically acceptable salt in some embodiments.
  • Pharmaceutically acceptable peptide salts are generally well known to those of ordinary skill in the art.
  • the biomimetic peptide or peptide agent may be formulated for intraocular injection (i.e., intravitreal injection) using a variety of pharmaceutically acceptable carriers, including, but not limited to, water, saline, dextrose solutions, etc.
  • the biomimetic peptides may be formulated and diluted in aqueous solutions, such as in physiologically compatible buffers.
  • the invention provides a method for preventing or treating an eye disease or condition involving Tie-2-related vascular permeability in a patient.
  • the method comprises administering the pharmaceutical composition described herein to the patient, at a dosing schedule (i.e., frequency) described herein.
  • a dosing schedule i.e., frequency
  • potent and long acting restoration of Tie2 activation can be achieved.
  • the method provides therapeutic benefit in conditions associated with edema or vascular permeability, including macular edema, diabetic macular edema (DME), and other conditions, including conditions characterized by acute or chronic ocular inflammation.
  • Tie2-related conditions include diabetic macular edema, retinal vein occlusion, wet AMD, background diabetic retinopathy.
  • the term“about” includes ⁇ 10% of the associated numerical value.
  • AXT107 and its derivative peptides are potent, safe, and have a surprisingly long duration of action with infrequent intravitreal injections of a small volume.
  • the invention thereby provides patient-friendly therapies for eye disease, including retinal disease such as wet AMD and diabetic macular edema.
  • Dutch Belted rabbits were anesthetized with an intramuscular injection of ketamine (25 mg/kg) and xylazine (2.5 mg/kg), and the pupils were dilated with 2.5% phenylephrine.
  • the conjunctiva was cleaned with 5% povidone-iodine and an intravitreous injection of 100 pg or 500 pg of AXT107 was given in one eye.
  • VFP vitreous fluorophotometry
  • This protocol of VEGF injection and VFP measurement was done on day 23 and day 30 of every subsequent month for 12 months.
  • the leakage each month in eyes administered AXT107 was normalized to animals injected with VEGF only, at the same time point. See FIGS. 1 A and IB.
  • AXT107 potently inhibits VEGF -induced vascular leakage in the rabbit eye, which is a better surrogate of human eye than mouse eye because of its size.
  • AXT107 potently inhibits VEGF-induced vascular leakage for at least 12 months in the rabbit eye.
  • FIGURE 2 AXT107 was injected into the vitreous of Dutch-Belted rabbits. The rabbits were then sacrificed at various time points, and the various ocular tissues were separated. The drug levels in the retina were measured by Liquid chromatography-mass spectrometry (LC/MS/MS). The drug levels were plotted as ng/g.
  • the Kd for binding of AXT107 to its integrin targets is 1-2 nM.
  • AXT107 is present at 100 ng/g or greater resulting in concentrations significantly greater than the Kd in the retina 225, 271, and 315 day time points.
  • FIGURE 3 AXT107 was injected into the vitreous of Dutch-Belted rabbits. One day later a gel was visible at the site of injection. The gel is marked by arrows in FIGURE 3. The retina with the optic nerve is visible in the back of the eye. The gel is compact and does not block the visual axis.
  • FIGURE 4 AXT107 formed a gel in the vitreous at the site of injection. The gel stayed in place and released the peptide in a sustained manner.
  • FIGURE 4 shows that the gel becomes smaller in place over time. At all time points, the back of the eye is clear, indicating that the peptide does not block the visual axis, and therefore, does not interfere with vision. The data of this experiment demonstrates that the peptide stays in place, and does not break apart or migrate for 15 months within the rabbit eye.
  • FIGURE 4 shows images of the gel over 301 days for AXT107 doses of 100 pg, 250 pg, 500 pg, and 1000 pg.
  • FIGURE 5 is a graph showing the release of AXT107 from gels over time. Dashed lines show an estimate of the AXT107 levels through 361 days.
  • AXT107 was put into vitreous from a 5yr old person and an 89yr old person. These pictures show that the peptide forms a gel in human vitreous that is similar to the one seen in the rabbit vitreous.
  • FIGURE 7 AXT107 was injected into the vitreous of Dutch-Belted rabbits in a PK toxicology study. When the animals were necropsied and the eyes examined, the gels formed by the peptide were visible in the vitreous at all doses. The size of the gels correlated with the dose as seen on the bottom of FIGURE 7 with the rulers (marked by arrows).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

In various aspects and embodiments, the invention provides methods and pharmaceutical compositions for treating ocular disease, including ocular disease involving ocular vascular permeability or ocular inflammation. In various aspects and embodiments, the invention comprises administering about 1 μg to about 1 mg of collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to about once every two years. In various embodiments, the methods and compositions provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.

Description

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE
PRIORITY
This application claims priority to, and the benefit of, US Provisional Application No. 62/824,017, filed March 26, 2019, which is hereby incorporated by reference in its entirety.
BACKGROUND
Diabetic macular edema (DME) and wet age-related macular degeneration (AMD) are the leading causes of blindness among adults. Progression of AMD leads to erosion of central vision, which is necessary for day-to-day activities such as reading, driving and identifying faces. While dry AMD leads to a gradual loss of vision, wet AMD leads to faster vision loss and is the most advanced form of the disease.
The introduction of injectable vascular endothelial growth factor (anti-VEGF) inhibitors (anti-VEGF drugs) has substantially lowered the incidence of AMD-related blindness, and allows many patients to maintain vision. These anti-VEGF drugs include ranibizumab (LUCENTIS) and aflibercept (EYLEA). During treatment, the ophthalmologist places anesthetic and antiseptic drops on the eye, then administers the anti-VEGF drug by injection into the vitreous (e.g., near the retina at the back of the eye). The recommended frequency of these injections varies from every few weeks to every few months. Patients often require multiple doses over the course of a few months, and repeat treatments are needed for continued benefit. The cost per treatment can be very high, around $2000 per injection in the U.S. Further, potential complications of intravitreal injection include infection (such as that caused by Streptococcus endophthalmitis ), retinal detachment, ocular hypertension, cataracts, inflammation, and others.
Accordingly, potent, safe, and patient-friendly therapies for eye disease, including retinal disease such as wet AMD and diabetic macular edema, are desirable. SUMMARY OF ASPECTS OF THE INVENTION
In various aspects and embodiments, the invention provides methods and pharmaceutical compositions for treating ocular disease, including retinal diseases involving vascular permeability and/or inflammation. In various aspects and embodiments, the invention comprises administering about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to no more frequent than about once every two years. As disclosed herein, the peptides form a clear gel upon intraocular injection, and provide a sustained release over an extended period, with a surprisingly small amount of active agent. Accordingly, the peptide can provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.
An exemplary collagen-IV-derived biomimetic peptide comprises, consists of, or consists essentially of the amino acid sequence LRRFSTAPFAFIDIMTVINF (SEQ ID NO: l). The collagen IV-derived biomimetic peptides promote the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature. The peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR). The peptide of SEQ ID NO: l is referred to herein as AXT107.
In some embodiments, the peptide or salt thereof is administered to a patient having a condition selected from diabetic macular edema, retinal vein occlusion, AMD (e.g., wet AMD), or background diabetic retinopathy. In some embodiments, the patient has acute or chronic inflammation of the eye. In some embodiments, the patient has uveitis or an autoimmune or inflammatory condition that manifests in the eye.
In various embodiments of the invention, about 1 mg or less of the collagen IV- derived biomimetic peptide, or salt thereof, is administered by intraocular injection. For example, the collagen IV-derived biomimetic peptide, or salt thereof, is administered at a dose of about 800 pg or less, or about 500 pg or less, or about 250 pg or less (e.g., from 50 to 150 pg) per intraocular inj ection. The small amount of active agent provides a surprisingly long duration of action, which substantially reduces the frequency of required injections. For example, the peptide or salt thereof may be administered by intraocular injection no more frequently than about once every three months, or no more frequently than about once every four months, or no more frequently than about once every six months, or no more frequently than about once every eight months, or no more frequently than about once every year, or no more frequently than about once every 1.5 years, or no more frequently than about once every two years, or no more frequently than about once every three years.
Further, in accordance with the invention, the peptide is delivered without the use of advanced formulation technologies (e.g., particle encapsulation), such as nanoparticle or microparticle encapsulation, or liposome encapsulation. That is, the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution). The physical properties of the peptide, which are observed to form a clear gel in the vitreous, are sufficient for potent and long duration of action.
In various embodiments, the peptide can be delivered for conditions (including macular edema, wet AMD) that are refractory or only partially-responsive to vascular endothelial growth factor (VEGF) blockade or inhibitor therapy.
In other aspects, the invention provides pharmaceutical compositions suitable for intravitreal injection. The pharmaceutical compositions comprise about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof (as disclosed herein) as a unit dose in a pre-filled syringe. For example, the unit dose may be about 700 pg or less of the peptide or salt thereof, or about 500 pg or less of the peptide or salt thereof, or about 250 pg or less of the peptide or salt thereof, or about 100 pg or less of the peptide or salt thereof. An exemplary composition comprises a dose of from 50 to 150 pg of peptide (e.g., about
100 pg).
Other aspects and embodiments of the invention will be apparent from the following detailed description.
DESCRIPTION OF THE FIGURES
FIGURE 1A and FIGURE IB are graphs showing AXT107 inhibition of VEGF- induced vascular leakage by dosing of 100 pg of AXT107 (FIGURE 1A) and 500 pg of AXT107 (FIGURE IB) over 12 Months in Dutch-Belted Rabbits. The“VEGF” bar indicates the no AXT107 control and is used to indicate the leakage that occurs in the absence of treatment with AXT107.
FIGURE 2 are graphs showing the amounts of AXT107 expressed as nanograms per gram (ng/g) that are present in the retina of Dutch-Belted Rabbits at various time points after intravitreal administration. AXT107 is found at significant levels in the retina 225, 271, and 315 days after a single injection.
FIGURE 3 is an image showing that AXT107 forms a gel upon injection in the rabbit eye. The gel remains below the visual axis, and does not block either the visual axis or the optic nerve.
FIG. 4 shows images of the gel over 301 days for AXT107 doses of 100 pg, 250 pg, 500 pg, and 1000 pg after a single injection.
FIGURE 5 is a graph showing the release of AXT107 from gels at 100 pg, 250 pg, 500 pg, and 1000 pg overtime. Dashed lines show an estimate of the AXT107 levels through 361 days.
FIGURE 6 is an image showing AXT107 gel formation in human vitreous of different ages.
FIGURE 7 are images showing gels formed by AXT107 in the rabbit eye from AXT107 PK toxicology study of different doses from Dutch-Belted necropsy rabbits at 6 Months after administration. Arrows point to isolated AXT107 gels.
DETAILED DESCRIPTION OF THE INVENTION
In various aspects and embodiments, the invention provides methods and pharmaceutical compositions for treating ocular disease, including retinal diseases involving vascular permeability and/or inflammation. In various aspects and embodiments, the invention comprises administering about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to no more than about once every two years. As disclosed herein, the peptides form a gel upon intraocular injection, and provide a sustained release over an extended period, with a surprisingly small amount of active agent. Accordingly, the peptide can provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.
In accordance with aspects of the invention, the active agent is a collagen IV-derived biomimetic peptide that promotes the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature and providing anti-inflammatory action. See WO 2018/067646, which is hereby incorporated by reference in its entirety.
The collagen IV-derived biomimetic peptides are derived from the a5 fibril of type IV collagen. Exemplary peptides comprise, consist of, or consist essentially of the amino acid sequence LRRFSTAPFAFIDIMDVINF (SEQ ID NO: l), or derivatives thereof. The peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR). The peptide of SEQ ID NO: l is referred to herein as AXT107.
Collagen IV-derived biomimetic peptides further include those described in US 9,056,923 and US 9,802,984, which are hereby incorporated by reference in their entireties. For example, peptides in accordance with the following disclosure include peptides comprising the amino acid sequence LRRFSTXPXXXXNINNVXNF (SEQ ID NO:2), where X is a standard amino acid or non-genetically encoded amino acid. In some embodiments, X at position 7 is M, A, or G; X at position 9 is F, A, Y, or G; X at position 10 is M, A, G, D-Alanine (dA), or norleucine (Me); X at position 11 is F, A, Y, G, or 4- chlorophenylalanine (4-ClPhe); X at position 12 and position 18 are independently selected from 2-Aminobutyric acid (Abu), G, S, A, V, T, I, L, or Allylglycine (AllylGly). In various embodiments, the peptide contains about 30 amino acids or less, or about 25 amino acids of less, or about 24 amino acids, or about 23 amino acids, or about 22 amino acids, or about 21 amino acids, or about 20 amino acids. In still other embodiments, one, two, three, four, or five amino acids of SEQ ID NO:2 are deleted. In some embodiments, the peptide comprises or consists of the amino acid sequence LRRFSTAPFAFINESiNVINF (SEQ ID NO:3). In some embodiments, the peptide comprises the amino acid sequence LRRFSTAPFAFIDINDVINF (SEQ ID NO: l), or derivative thereof. Derivatives of the peptide of SEQ ID NO: l include peptides having from 1 to 5 amino acid substitutions, insertions, or deletions ( e.g ., 1, 2, 3, 4, or 5 amino acid substitutions, insertions, or deletions collectively) with respect to SEQ ID NO: l, although in some embodiments the Asp at positions 13 and 16 are maintained. In some embodiments, the sequence DINDV is maintained in the derivative. The peptide may have the amino acid sequence of LRRFSTXPXXXXDINDVXNF, where X is a standard amino acid or non-genetically encoded amino acid (SEQ ID NO:4). In some embodiments, X at position 7 is M, A, or G; X at position 9 is F, A, Y, or G; X at position 10 is M, A, G, D-Alanine (dA), or norleucine (Me); X at position 11 is F, A, Y, G, or 4-chlorophenylalanine (4-ClPhe); X at position 12 and position 18 are independently selected from 2-Aminobutyric acid (Abu), G, S, A, V, T, I, L, or Allylglycine (AllylGly). In various embodiments, the peptide contains about 30 amino acids or less, or about 25 amino acids of less, or about 24 amino acids, or about 23 amino acids, or about 22 amino acids, or about 21 amino acids, or about 20 amino acids. In still other embodiments, one, two, three, four, or five amino acids of SEQ ID NO:4 or SEQ ID NO: 1 are deleted.
In some embodiments, amino acid substitutions are made at any position of a peptide of SEQ ID NO: l or 3, which can be independently selected from conservative or non conservative substitutions. In these or other embodiments, the peptide includes from 1 to 10 amino acids added to one or both termini (collectively). The N- and/or C-termini may optionally be occupied by another chemical group (other than amine or carboxy, e.g., amide or thiol).
Conservative substitutions may be made, for instance, on the basis of similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the amino acid residues involved. The 20 genetically encoded amino acids can be grouped into the following six standard amino acid groups:
(1) hydrophobic: Met, Ala, Val, Leu, lie;
(2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gin; (3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro; and
(6) aromatic: Trp, Tyr, Phe.
As used herein,“conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed within the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains one negative charge in the so modified polypeptide. In addition, glycine and proline may be substituted for one another based on their ability to disrupt a-helices. Some preferred conservative substitutions within the above six groups are exchanges within the following sub-groups: (i) Ala, Val, Leu and He; (ii) Ser and Thr; (iii) Asn and Gin; (iv) Lys and Arg; and (v) Tyr and Phe.
As used herein,“non-conservative substitutions” are defined as exchanges of an amino acid by another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.
In various embodiments, the biomimetic peptide or peptide agent is a peptide of from about 8 to about 30 amino acids, or from about 10 to about 20 amino acids, and has at least 4, at least 5, or at least 6 contiguous amino acids of SEQ ID NO: 1 or 3. In some embodiments, the peptide contains at least one, at least two, or at least three d-amino acids. In some embodiments, the peptide contains from one to about five ( e.g 1, 2, or 3) non- genetically encoded amino acids, which are optionally selected from 2-Aminobutyric acid (Abu), norleucine (Me), 4-chlorophenylalanine (4-ClPhe), and Allylglycine (AllylGly).
Exemplary biomimetic peptides in accordance with the disclosure include:
LRRF S TMPFMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 5),
LRRF S TMP AMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 6),
LRRF S TMPF AF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 7),
LRRF S TMPFM A( Abu)NINN V ( Abu)NF (SEQ ID NO: 8), LRRF S TMPF (N1 e)F ( Abu)NINN V ( Abu)NF (SEQ ID NO: 9),
LRRF STMPFM(4-ClPhe)( Abu)NINN V (Abu)NF (SEQ ID NO: 10),
LRRF S TMPFMF SNINN V SNF (SEQ ID NO: 11),
LRRF S TMPFMF ANINN V ANF (SEQ ID NO: 12), LRRF STMPFMFININNVINF (SEQ ID NO: 13),
LRRF S TMPFMF TNINN VTNF (SEQ ID NO: 14),
LRRF STMPFMF (Ally Gly)NINNV (Ally Gly)NF (SEQ ID NO: 15),
LRRF STMPFMF VNINNVVNF (SEQ ID NO: 16),
LRRF STMPF dAFININNVINF (SEQ ID NO: 17), LRRF STMPF AFININNVINF (SEQ ID NO: 18),
LRRFSTAPFAFININNVINF (SEQ ID NO: 19),
LRRFSTAPFdAFIDINDVINF (SEQ ID NO:20),
LRRFSTAPFAFIDINDVINW (SEQ ID NO:21), dLRRdLRRFSTAPFAFIDINDVINF (SEQ ID NO:22), LRRF S T APF AFIDIND VIN dF (SEQ ID NO:23),
dLRRFSTAPFAFIDINDVINdF (SEQ ID NO:24).
F ( Abu)NINN V ( Abu)N (SEQ ID NO:25),
FTNINNVTN (SEQ ID NO:26),
FININNVINF (SEQ ID NO:27),
F SNINN V SNF (SEQ ID NO:28), FANINNVANF (SEQ ID NO:29),
F(AllyGly)NINNV(AllyGly)NF (SEQ ID NO: 30),
FVNINNVVNF (SEQ ID NO:31),
FIDINDVINF (SEQ ID NO:32),
FIDINDVINW (SEQ ID NO:33),
FTDINDVTN (SEQ ID NO: 34),
A( Abu)NINN V ( Abu)NF (SEQ ID NO:35), or
(4-ClPhe)(Abu)NINNV(Abu)NF (SEQ ID NO: 36).
In various embodiments, the biomimetic peptide forms a gel in human vitreous.
In some embodiments, the peptide or salt thereof is administered to a patient having a condition selected from diabetic macular edema, retinal vein occlusion, AMD (e.g., wet AMD), or background diabetic retinopathy. In some embodiments, the patient has acute or chronic inflammation of the eye. In some embodiments, the patient has uveitis or an autoimmune or inflammatory condition that manifests in the eye.
In some embodiments, the patient has macular edema. Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell. The causes of macular edema include chronic or uncontrolled diabetes type 2 (e.g., diabetic retinopathy), in which peripheral blood vessels including those of the retina leak fluid into the retina. Other causes and/or associated disorders include age-related macular degeneration (AMD), chronic uveitis, atherosclerosis, high blood pressure and glaucoma. In some embodiments, the patient has or is at risk of retinal vein occlusion, which can lead to severe damage to the retina and blindness, due to ischemia and edema.
In some embodiments, the patient has AMD, which is optionally wet AMD or in some embodiments dry AMD. The present invention in various embodiments provides for treatment of retinal disease with intravitreal injections of a collagen IV-derived biomimetic peptide, which only requires a small amount of active agent to be administered with infrequent injections. Generally, an intravitreal injection is an injection into the eye, and in particular the vitreous which is a jelly-like fluid that fills the eye. During the procedure, for example as is used conventionally for administering anti-VEGF drugs, the health care provider injects medicine into the vitreous, near the retina at the back of the eye. The procedure often takes about 15 to 30 minutes. For example, the procedure generally involves placing drops in the eyes to dilate the pupils, numbing drops are placed in the eye, and drug is injected into the eye with a small needle. Antibiotic drops may also be used to prevent infection. While the procedure is routine, it does not come without risks and potential complications. These include endophthalmitis, intraocular inflammation, retinal detachment, intraocular pressure elevation, ocular hemorrhage, in addition to systemic side effects. See, Falavarjani KG and Nguyen QD, Adverse events and complications associated with intravitreal injection of anti- VEGF agents: a review of literature. Eye 2013 Jul; 27(7): 787-794. Further, the procedure for administering conventional anti-VEGF drugs is costly and not convenient since frequent injections are generally required.
In various embodiments of the invention, about 1 mg or less of the collagen IV- derived biomimetic peptide, or salt thereof, is administered by intraocular injection. In various embodiments, the unit dose of peptide is administered at the bottom of the eye, such as between 5:00 and 7:00, so that gel forms at the bottom. For example, the collagen IV- derived biomimetic peptide, or salt thereof, is administered at a dose of from about 25 pg to about 1000 pg. For example, about 800 pg or less, or about 700 pg or less, or about 500 pg or less, or about 250 pg or less, or about 100 pg or less of the peptide or salt thereof is administered per intraocular injection. In such embodiments, at least about 25 pg or at least about 50 pg is administered per intraocular injection. In some embodiments, the unit dose is greater than 1 mg, such as from 1 mg to about 2 mg. The small amount of active agent provides a surprisingly long duration of action, which substantially reduces the frequency of required injections. For example, the peptide or salt thereof may be administered by intraocular injection no more frequently than about once every three months, or no more frequently than about once every four months, or no more frequently than about once every six months, or no more frequently than about once every eight months, or no more frequently than about once every year, or no more frequently than about once every 1.5 years, or no more frequently than about once every two years, or no more frequently than about once every three years.
Further, in accordance with the invention, the peptide is delivered without the use of advanced formulation technologies (e.g., particle encapsulation), such as nanoparticle or microparticle encapsulation, or liposome encapsulation. That is, the peptide is delivered without any encapsulation technology (e.g., the peptide is delivered as a“naked peptide” in aqueous solution). The physical properties of the peptide, which are observed to form a gel in the vitreous, are sufficient for potent and long duration of action.
Unless specifically stated or obvious from context, as used herein, the term“about” includes values within plus or minus 10% of a stated value.
In various embodiments, about 10 pg to about 50 pg of the collagen IV-derived biomimetic peptide, or salt thereof, is administered per intraocular injection, and at a frequency of about once per month or about once every other month. For example, about 25 pg of the peptide or salt thereof may be administered by intraocular injection about monthly. Alternatively, about 50 pg to about 150 pg per intraocular injection is administered at a frequency of no more than about once every third month, or no more frequently than about once every fourth month, or no more frequently than about once every six months. For example, the peptide or salt thereof may be administered at about 50 pg and at a frequency of about once every three or four months. In some embodiments, the peptide or salt thereof is administered at about 100 pg to about 150 pg per injection, and at a frequency of about once every five to seven months, and optionally about once every six months. In some embodiments, the dose of 100 to 150 pg is administered about once every eight months or about once every nine months.
In other embodiments, the amount of active agent delivered per injection is increased, providing unexpected durations of action. For example, the collagen IV-derived biomimetic peptide or salt thereof may be administered at about 150 pg to about 250 pg per intraocular injection, and at a frequency of no more than about once every six months. For example, in these embodiments, the peptide or salt thereof may be administered no more frequently than about once every eight months. In some embodiments, the peptide or salt thereof is administered no more frequently than about once every ten months or about once every twelve months. In some embodiments, the peptide or salt thereof is administered at about 200 pg and at a frequency of about once every six to eight months. In some embodiments, the peptide or salt thereof is administered at about 250 pg and at a frequency of about once every six to twelve months.
In still other embodiments, the peptide or salt thereof is administered at from about 250 pg to about 1 mg per intraocular injection, and at a frequency of no more than about once every six months. In these embodiments, the peptide or salt thereof is administered at about 300 pg to about 700 pg per injection, or is administered at about 400 pg to about 700 pg per injection, or is administered at about 500 pg to about 700 pg per injection, or is administered at about 600 pg to about 700 pg per injection. In some embodiments, the peptide or salt thereof is administered at a frequency of about once every six to twelve months. For example, the peptide or salt thereof is administered about once every seven months, about once every eight months, about once every nine months, about once every ten months, about once every eleven months, or about once every twelve months, or about once every 18 months.
In still further embodiments, the peptide or salt thereof is administered at from about 700 pg to about 1 mg per intraocular injection, and at a frequency of no more than once every twelve months or no more than once every 15 months. In some embodiments, the peptide or salt thereof is administered at about 800 pg to about 1 mg per injection, or is administered at about 900 pg to about 1 mg per injection, or is administered at a frequency of once every twelve to eighteen months. In some embodiments, the peptide or salt thereof is administered about once every two years or about once every three years.
In some embodiments, the peptide dosed as described above, is the peptide consisting of SEQ ID NO: l (AXT107).
In various embodiments, the patient will receive a plurality of doses, and in some embodiments, therapy can be continuous at the recommended frequency of injections for disease control or management. In some embodiments, therapy need not be continuous, where symptoms or disease has been substantially alleviated. In various embodiments, the patient receives at least two injections, or at least four injections, or at least six injections, or at least eight injections, or at least ten injections. In some embodiments, injections are provided in a regimen of from four to ten injections.
The collagen IV-derived peptide promotes the Tie2 agonist activities of Angiopoietin 2 (Ang2), thereby stabilizing vasculature. The peptides target and disrupt a5b1 and anb3 integrins, and inhibit signaling through multiple receptors, including vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (HGFR), insulin-like growth factor receptor (IGFR), and epidermal growth factor receptor (EGFR). Accordingly, the peptides disclosed herein provide a potent alternative to VEGF blockade or inhibitor therapy, or potent combination therapy.
In various embodiments, the peptide can be delivered for conditions (including macular edema, wet AMD) that are refractory or only partially-responsive to vascular endothelial growth factor (VEGF) blockade or inhibitor therapy. Pharmaceutical agents that block VEGF include aflibercept, bevacizumab, ranibizumab, and ramucirumab, and similar agents, which are administered to slow or block angiogenesis. Other agents that target VEGF-mediated biological activity include kinase inhibitors such as pazopanib, sorafenib, sunitinib, axitinib, ponatinib, lenvatinib, vandetanib, regorafenib, and cabozantinib.
Aflibercept is a biopharmaceutical drug for the treatment of wet macular degeneration (EYLEA). Aflibercept is an inhibitor of VEGF, and is a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, that are fused to the Fc portion of the human IgGl immunoglobulin. Aflibercept binds to VEGFs and acts like a“VEGF trap”, inhibiting the activity of the vascular endothelial growth factor subtypes VEGF -A and VEGF-B, as well as to placental growth factor (PGF).
Bevacizumab (AVASTIN) is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting VEGF-A. Bevacizumab is administered for treating certain metastatic cancers, including colon cancer, lung cancers ( e.g NSCLC), renal cancers, ovarian cancers, breast cancer, and glioblastoma. Bevacizumab can also be used for treatment of eye diseases, including AMD and diabetic retinopathy. Ranibizumab (LUCENTIS) is a monoclonal antibody fragment (Fab), and is administered for treatment of wet AMD. The drug is injected intravitreally (into the vitreous humour of the eye) about once a month. Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting VEGF A, similar to Bevacizumab.
The biomimetic peptide may be administered after unsuccessful VEGF blockade therapy, that is, where reductions in angiogenesis, lymphangiogenesis, and/or edema were not observed. In some embodiments, the peptide is administered as an alternative to VEGF blockade therapy. In still further embodiments, the peptide is administered in combination with VEGF blockade therapy, either simultaneously with, before, or after a VEGF blockade regimen. By activating Tie2 signaling, the biomimetic peptides or peptide agents provide therapeutic benefits that may not be observed with VEGF blockage therapy, or VEGF blockade therapy alone.
Therefore, in some embodiments, the peptide or salt thereof is administered after unsuccessful VEGF blockade or inhibitor therapy. In some embodiments, the patient has a condition that is refractory or only partially-responsive to VEGF blockade or inhibitor therapy.
In other aspects, the invention provides pharmaceutical compositions suitable for intravitreal injection. The pharmaceutical compositions comprise about 1 pg to about 1 mg or about 25 pg to about 800 pg of a collagen IV-derived biomimetic peptide or salt thereof (as disclosed herein) as a unit dose in a pre-filled syringe. For example, the unit dose may be about 700 pg or less of the peptide or salt thereof, or about 500 pg or less of the peptide or salt thereof, or about 250 pg or less of the peptide or salt thereof, or about 100 pg or less of the peptide or salt thereof. Exemplary unit doses include about 100 pg, about 250 pg, about 500 pg, and about 750 pg.
In some embodiments, the composition has a unit dose of from about 10 pg to about 50 pg of the peptide or salt thereof. In other embodiments, the composition has a unit dose of from about 50 pg to about 150 pg (e.g., about 100 pg) of the peptide or salt thereof. In some embodiments, the composition has a unit dose of from about 150 pg to about 250 pg of the peptide or salt thereof. In some embodiments, the composition has a unit dose of from about 250 pg to about 700 pg, or about 300 pg to about 700 pg, or about 400 pg to about 700 pg, or about 500 pg to about 700 pg, or about 600 pg to about 700 pg of the peptide or salt thereof.
In still other embodiments, the pharmaceutical composition has a unit dose of from about 700 pg to about 1 mg, or from about 800 pg to about 1 mg, of the peptide or salt thereof. In some embodiments, the unit dose is about 1 mg. In some embodiments, the unit dose is greater than 1 mg, such as from about 1 mg to about 2 mg.
The unit dose volume (in accordance with the compositions and methods described herein) may be in the range of about 1 mΐ to about 1 mL, or from about 10 pL to about 0.5 mL, or from about 10 pL to about 250 pL, or from about 10 pL to about 50 pL. In some embodiments, the pharmaceutical composition comprises a unit volume of from about 25 pL to about 0.5 mL, or a unit volume of from about 25 pL to about 200 pL, or a unit volume of from about 25 pL to about 100 pL. In some embodiments, the unit volume is less than about 100 pL, or less than about 50 pL, or less than about 25 pL. In various embodiments, the volume is about 50 pL.
The biomimetic peptides or peptide agents can be chemically synthesized and purified using well-known techniques, such as solid-phase synthesis. See US 9,051,349, which is hereby incorporated by reference in its entirety.
Peptides may be provided in the form of a pharmaceutically acceptable salt in some embodiments. Pharmaceutically acceptable peptide salts are generally well known to those of ordinary skill in the art.
The biomimetic peptide or peptide agent may be formulated for intraocular injection (i.e., intravitreal injection) using a variety of pharmaceutically acceptable carriers, including, but not limited to, water, saline, dextrose solutions, etc. The biomimetic peptides may be formulated and diluted in aqueous solutions, such as in physiologically compatible buffers.
In certain aspects, the invention provides a method for preventing or treating an eye disease or condition involving Tie-2-related vascular permeability in a patient. The method comprises administering the pharmaceutical composition described herein to the patient, at a dosing schedule (i.e., frequency) described herein. In accordance with embodiments of the invention, with only small amounts of active agent and infrequent injection of unit doses, potent and long acting restoration of Tie2 activation can be achieved. In various embodiments, the method provides therapeutic benefit in conditions associated with edema or vascular permeability, including macular edema, diabetic macular edema (DME), and other conditions, including conditions characterized by acute or chronic ocular inflammation. Tie2-related conditions include diabetic macular edema, retinal vein occlusion, wet AMD, background diabetic retinopathy.
As used herein, the term“about” includes ±10% of the associated numerical value.
As used in this Specification and the appended claims, the singular forms“a,”“an” and“the” include plural referents unless the context clearly dictates otherwise.
Unless specifically stated or obvious from context, as used herein, the term“or” is understood to be inclusive and covers both“or” and“and”.
The invention will further be described in accordance with the following non limiting examples.
EXAMPLES
The following examples demonstrate that AXT107 and its derivative peptides are potent, safe, and have a surprisingly long duration of action with infrequent intravitreal injections of a small volume. The invention thereby provides patient-friendly therapies for eye disease, including retinal disease such as wet AMD and diabetic macular edema.
In these experiments, Dutch Belted rabbits were anesthetized with an intramuscular injection of ketamine (25 mg/kg) and xylazine (2.5 mg/kg), and the pupils were dilated with 2.5% phenylephrine. The conjunctiva was cleaned with 5% povidone-iodine and an intravitreous injection of 100 pg or 500 pg of AXT107 was given in one eye. Twenty-three days after injection of AXT107, 10 pg of VEGF was injected into the vitreous and 7 days later, 30 days after the initial AXT107 injection, vitreous fluorophotometry (VFP) was performed with a Fluorotron Master™ ocular fluorophotometer fitted with an animal adapter (OcuMetrics, Mountain View, CA). For VFP, 15 mg of sodium fluorescein (AK-Fluor 10%, Akorn, Lake Forest, IL) was injected into an ear vein, and after one-hour fluorescence was measured along the visual axis from the retina to the cornea. The area under the fluorescein concentration curve between 5 and 7 mm was calculated in front of the retina to determine the extent of leakage. This protocol of VEGF injection and VFP measurement was done on day 23 and day 30 of every subsequent month for 12 months. The leakage each month in eyes administered AXT107 was normalized to animals injected with VEGF only, at the same time point. See FIGS. 1 A and IB.
The results of these experiments show that AXT107 potently inhibits VEGF -induced vascular leakage in the rabbit eye, which is a better surrogate of human eye than mouse eye because of its size. In addition, AXT107 potently inhibits VEGF-induced vascular leakage for at least 12 months in the rabbit eye. In FIGURE 2, AXT107 was injected into the vitreous of Dutch-Belted rabbits. The rabbits were then sacrificed at various time points, and the various ocular tissues were separated. The drug levels in the retina were measured by Liquid chromatography-mass spectrometry (LC/MS/MS). The drug levels were plotted as ng/g. The Kd for binding of AXT107 to its integrin targets is 1-2 nM. AXT107 is present at 100 ng/g or greater resulting in concentrations significantly greater than the Kd in the retina 225, 271, and 315 day time points.
In FIGURE 3, AXT107 was injected into the vitreous of Dutch-Belted rabbits. One day later a gel was visible at the site of injection. The gel is marked by arrows in FIGURE 3. The retina with the optic nerve is visible in the back of the eye. The gel is compact and does not block the visual axis.
In FIGURE 4, AXT107 formed a gel in the vitreous at the site of injection. The gel stayed in place and released the peptide in a sustained manner. FIGURE 4 shows that the gel becomes smaller in place over time. At all time points, the back of the eye is clear, indicating that the peptide does not block the visual axis, and therefore, does not interfere with vision. The data of this experiment demonstrates that the peptide stays in place, and does not break apart or migrate for 15 months within the rabbit eye. FIGURE 4 shows images of the gel over 301 days for AXT107 doses of 100 pg, 250 pg, 500 pg, and 1000 pg. FIGURE 5 is a graph showing the release of AXT107 from gels over time. Dashed lines show an estimate of the AXT107 levels through 361 days.
In the tube in FIGURE 6, AXT107 was put into vitreous from a 5yr old person and an 89yr old person. These pictures show that the peptide forms a gel in human vitreous that is similar to the one seen in the rabbit vitreous.
In FIGURE 7, AXT107 was injected into the vitreous of Dutch-Belted rabbits in a PK toxicology study. When the animals were necropsied and the eyes examined, the gels formed by the peptide were visible in the vitreous at all doses. The size of the gels correlated with the dose as seen on the bottom of FIGURE 7 with the rulers (marked by arrows).

Claims

CLAIMS:
1. A method for preventing or treating a condition involving ocular vascular permeability or inflammation in a patient, comprising: administering a unit dose of a collagen IV-derived biomimetic peptide or salt thereof to said patient by intraocular inj ection at a frequency of no more than about once every month.
2. The method of claim 1, wherein the unit dose comprises about 10 pg to about 1 mg of the peptide.
3. The method of claim 2, wherein the unit dose is formulated as a naked peptide in aqueous solution without particle encapsulation.
4. The method of claim 1, wherein the patient has a condition selected from diabetic macular edema, retinal vein occlusion, wet age-related macular degeneration (wet AMD), or background diabetic retinopathy.
5. The method of claim 1, wherein the patient has acute or chronic inflammation of the eye.
6. The method of claim 5, wherein the patient has uveitis.
7. The method of claim 5, wherein the inflammation is associated with an autoimmune condition.
8. The method of claim 7, wherein the unit dose comprises about 700 pg or less, or about 500 pg or less, of the peptide or salt thereof.
9. The method of claim 8, wherein the unit dose comprises about 250 pg or less of the peptide or salt thereof.
10. The method of claim 9, wherein the unit dose comprises about 100 pg or less of the peptide or salt thereof.
11. The method of any one of claims 1 to 10, wherein the unit dose is administered by intraocular injection no more frequently than once every three months.
12. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every four months.
13. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every six months.
14. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every eight months.
15. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every year.
16. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every 18 months.
17. The method of claim 11, wherein the unit dose is administered by intraocular injection no more frequently than once every 2 years.
18. The method of any one of claims 1 to 7, wherein the unit dose comprises about 10 pg to about 50 pg of the peptide or salt thereof, and is administered at a frequency of no more than about monthly.
19. The method of claim 18, wherein the unit dose comprises about 25 pg of the peptide or salt thereof, and the unit dose is administered by intraocular injection about monthly.
20. The method of any one of claims 1 to 7, wherein the unit dose comprises about 50 pg to about 150 pg of the peptide or salt thereof, and the unit dose is administered by intraocular injection at a frequency of no more than once every third month.
21. The method of claim 20, wherein the unit dose is administered no more frequently than once every fourth month.
22. The method of claim 20, wherein the unit dose is administered no more frequently than once every six months.
23. The method of claim 20, wherein the unit dose comprises about 50 pg of the peptide or salt thereof, and the unit dose is administered at a frequency of once every three or four months.
24. The method of claim 20, wherein the unit dose comprises about 100 pg to about 150 pg of the peptide or salt thereof, and the unit dose is administered at a frequency of once every five to seven months, and optionally once every six months.
25. The method of any one of claims 1 to 7, wherein the unit dose comprises about 150 pg to about 250 pg of the peptide or salt thereof, and is administered at a frequency of no more than once every six months.
26. The method of claim 25, wherein the unit dose is administered no more frequently than once every eight months.
27. The method of claim 25, wherein the unit dose is administered no more frequently than once every twelve months.
28. The method of claim 25, wherein the unit dose comprises from about 200 pg to about 250 of the peptide or salt thereof, and is administered at a frequency of once every six to twelve months.
29. The method of any one of claims 1 to 7, wherein the unit dose comprises from about 250 pg to about 700 pg of the peptide or salt thereof, and is administered at a frequency of no more than once every six months.
30. The method of claim 29, wherein the unit dose comprises about 300 pg to about 700 pg of the peptide or salt thereof.
31. The method of claim 29, wherein the unit dose comprises about 400 pg to about 700 pg of the peptide or salt thereof.
32. The method of claim 29, wherein the unit dose comprises about 500 pg to about 700 pg of the peptide of salt thereof.
33. The method of claim 29, wherein the unit dose comprises about 600 pg to about 700 pg of the peptide or salt thereof.
34. The method of any one of claims 29 to 33, wherein the unit dose is administered at a frequency of once every six to eighteen months.
35. The method of claim 34, wherein the unit dose is administered about once every seven months, about once every eight months, about once every nine months, about once every ten months, about once every eleven months, or about once every twelve months, or about one every eighteen months.
36. The method of any one of claims 1 to 7, wherein the unit dose comprises about 700 pg to about 1 mg of the peptide or salt thereof, and the unit dose is administered at a frequency of no more than once every twelve months.
37. The method of claim 36, wherein the unit dose comprises about 800 pg to about 1 mg of the peptide or salt thereof.
38. The method of claim 36, wherein the unit dose comprises about 900 pg to about 1 mg of the peptide or salt thereof.
39. The method of any one of claims 36 to 38, wherein the unit dose is administered at a frequency of once every twelve months to once every two years.
40. The method of claim 39, wherein the unit dose is administered about once every eighteen months to about once every two years.
41. The method of any one of claims 1 to 40, wherein the peptide or salt thereof is administered after unsuccessful VEGF blockade or inhibitor therapy.
42. The method of any one of claims 1 to 40, wherein the patient’ s condition is refractory or only partially-responsive to VEGF blockade or inhibitor therapy.
43. The method of any one of claims 1 to 40, wherein the peptide or salt thereof is administered as an alternative to VEGF blockade or inhibitor therapy.
44. The method of any one of claims 1 to 40, wherein the peptide or salt thereof is administered in combination with VEGF blockade therapy.
45. The method of any one of claims 1 to 44, wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs: 1 to 36.
46. The method of any one of claims 1 to 44, wherein the peptide is derived from the a5 fibril of collagen IV, or a biomimetic thereof.
47. The method of claim 45 or 46, wherein the peptide is:
LRRF S TMPFMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 5),
LRRF S TMP AMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 6), LRRF S TMPF AF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 7),
LRRF S TMPFM A( Abu)NINN V ( Abu)NF (SEQ ID NO: 8),
LRRF S TMPF (N1 e)F ( Abu)NINN V ( Abu)NF (SEQ ID NO: 9),
LRRF STMPFM(4-ClPhe)( Abu)NINN V (Abu)NF (SEQ ID NO: 10), LRRF S TMPFMF SNINN V SNF (SEQ ID NO: 11),
LRRF S TMPFMF ANINN V ANF (SEQ ID NO: 12),
LRRF STMPFMFININNVINF (SEQ ID NO: 13),
LRRF S TMPFMF TNINN VTNF (SEQ ID NO: 14),
LRRF STMPFMF ( Ally Gly)NINNV ( Ally Gly)NF (SEQ ID NO: 15), LRRFSTMPFMFVNINNVVNF (SEQ ID NO: 16),
LRRF STMPF dAFININNVINF (SEQ ID NO: 17),
LRRFSTMPFAFININNVINF (SEQ ID NO: 18),
LRRFSTAPFAFININNVINF (SEQ ID NO: 19),
LRRFSTAPFdAFIDINDVINF (SEQ ID NO:20),
LRRFSTAPFAFIDINDVINW (SEQ ID NO:21),
dLRRdLRRFSTAPFAFIDINDVINF (SEQ ID NO:22),
LRRFSTAPFAFIDINDVINdF (SEQ ID NO:23), or
dLRRFSTAPFAFIDINDVINdF (SEQ ID NO:24).
48. The method of claim 45 or 46, wherein the peptide is:
F ( Abu)NINN V ( Abu)N (SEQ ID NO:25),
FTNINNVTN (SEQ ID NO:26),
FININNVINF (SEQ ID NO:27),
FSNINNVSNF (SEQ ID NO:28),
FANINNVANF (SEQ ID NO:29),
F(AllyGly)NINNV(AllyGly)NF (SEQ ID NO: 30),
FVNINNVVNF (SEQ ID NO:31),
FIDINDVINF (SEQ ID NO:32),
FIDINDVINW (SEQ ID NO:33),
FTDINDVTN (SEQ ID NO: 34),
A( Abu)NINN V ( Abu)NF (SEQ ID NO:35), or (4-ClPhe)(Abu)NINNV(Abu)NF (SEQ ID NO: 36).
49. The method of claim 46, wherein the peptide has the amino acid sequence LRRFSTAPFAFIDINDVINF (SEQ ID NO: l).
50. The method of any one of claims 1 to 49, wherein the unit dose has a volume in the range of about 1 mΐ to about 1 mL, or a volume in the range of about 10 pL to about 0.5 mL, or a volume in the range of about 10 pL to about 250 pL, or a volume in the range of about 10 pL to about 50 pL.
51. The method of claim 50, wherein the unit dose has a volume in the range of about 25 pL to about 0.5 mL, or a volume in the range of about 25 pL to about 200 pL, or a volume in the range of about 25 pL to about 100 pL.
52. The method of claim 50, wherein the unit volume is less than about 100 pL, or less than about 50 pL, or less than about 25 pL.
53. A pharmaceutical composition suitable for intravitreal injection, comprising about 1 pg to about 1 mg of a collagen IV-derived biomimetic peptide or salt thereof as a unit dose in a pre-filled syringe, the peptide being formulated in an aqueous solution without particle encapsulation.
54. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 1 mg of the peptide of salt thereof.
55. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 700 pg of the peptide or salt thereof.
56. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 500 pg or less of the peptide or salt thereof.
57. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 250 pg or less of the peptide or salt thereof.
58. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 100 pg or less of the peptide or salt thereof.
59. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 10 pg to about 50 pg of the peptide or salt thereof.
60. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 50 pg to about 150 pg of the peptide or salt thereof.
61. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 150 pg to about 250 pg of the peptide or salt thereof.
62. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 250 pg to about 700 pg of the peptide or salt thereof.
63. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 300 pg to about 700 pg of the peptide or salt thereof.
64. The pharmaceutical composition of claim 53, wherein the unit dose comprises about 400 pg to about 700 pg of the peptide or salt thereof.
65. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 500 pg to about 700 pg of the peptide or salt thereof.
66. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 600 pg to about 700 pg of the peptide or salt thereof.
67. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 700 pg to about 1 mg of the peptide or salt thereof.
68. The pharmaceutical composition of claim 53, wherein the unit dose comprises from about 800 pg to about 1 mg of the peptide or salt thereof.
69. The pharmaceutical composition of any one of claims 53 to 68, wherein the unit dose has a volume in the range of about 1 pi to about 1 mL, or a volume in the range of about 10 pL to about 0.5 mL, or a volume in the range of about 10 pL to about 250 pL, or a volume in the range of about 10 pL to about 50 pL.
70. The pharmaceutical composition of claim 69, wherein the unit dose has a volume in the range of about 25 pL to about 0.5 mL, or a volume in the range of about 25 pL to about 200 pL, or a volume in the range of about 25 pL to about 100 pL.
71. The pharmaceutical composition of claim 70, wherein the unit dose has a volume of less than about 100 pL, or less than about 50 pL, or less than about 25 pL.
72. The pharmaceutical composition of any one of claims 53 to 71, wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs: 1 to 36 or a derivative thereof.
73. The pharmaceutical composition of claim 72, wherein the peptide has the amino acid sequence of SEQ ID NO: 1.
74. The pharmaceutical composition of claim 72, wherein the peptide has an amino acid sequence selected from:
LRRF S TMPFMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 5),
LRRF S TMP AMF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 6),
LRRF S TMPF AF ( Abu)NINN V ( Abu)NF (SEQ ID NO: 7),
LRRF S TMPFM A( Abu)NINN V ( Abu)NF (SEQ ID NO: 8), LRRF S TMPF (N1 e)F ( Abu)NINN V ( Abu)NF (SEQ ID NO: 9),
LRRF STMPFM(4-ClPhe)( Abu)NINN V (Abu)NF (SEQ ID NO: 10),
LRRF S TMPFMF SNINN V SNF (SEQ ID NO: 11),
LRRF S TMPFMF ANINN V ANF (SEQ ID NO: 12),
LRRF STMPFMFININNVINF (SEQ ID NO: 13),
LRRF S TMPFMF TNINN VTNF (SEQ ID NO: 14),
LRRF STMPFMF (Ally Gly)NINNV (Ally Gly)NF (SEQ ID NO: 15),
LRRFSTMPFMFVNINNVVNF (SEQ ID NO: 16),
LRRF STMPF dAFININNVINF (SEQ ID NO: 17),
LRRFSTMPFAFININNVINF (SEQ ID NO: 18),
LRRFSTAPFAFININNVINF (SEQ ID NO: 19),
LRRFSTAPFdAFIDINDVINF (SEQ ID NO:20),
LRRFSTAPFAFIDINDVINW (SEQ ID NO:21),
dLRRdLRRFSTAPFAFIDINDVINF (SEQ ID NO:22),
LRRFSTAPFAFIDINDVINdF (SEQ ID NO:23), or
dLRRFSTAPFAFIDINDVINdF (SEQ ID NO:24).
75. The pharmaceutical composition of claim 72, wherein the amino acid sequence of the peptide is selected from:
F ( Abu)NINN V ( Abu)N (SEQ ID NO:25),
FTNINNVTN (SEQ ID NO:26),
FININNVINF (SEQ ID NO:27),
FSNINNVSNF (SEQ ID NO:28),
FANINNVANF (SEQ ID NO:29),
F(AllyGly)NINNV(AllyGly)NF (SEQ ID NO: 30),
FVNINNVVNF (SEQ ID NO:31),
FIDINDVINF (SEQ ID NO:32),
FIDINDVINW (SEQ ID NO:33),
FTDINDVTN (SEQ ID NO: 34),
A( Abu)NINN V ( Abu)NF (SEQ ID NO:35), or
(4-ClPhe)(Abu)NINNV(Abu)NF (SEQ ID NO: 36).
PCT/US2020/024972 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease Ceased WO2020198481A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US17/442,682 US12540171B2 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease
CA3134816A CA3134816A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease
JP2021557369A JP7650074B2 (en) 2019-03-26 2020-03-26 Compositions and methods for treating eye diseases
KR1020217034683A KR20210146352A (en) 2019-03-26 2020-03-26 Compositions and methods for treating eye diseases
AU2020248438A AU2020248438A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease
MX2021011727A MX2021011727A (en) 2019-03-26 2020-03-26 COMPOSITIONS AND METHODS FOR TREATING EYE DISEASES.
EP20776493.7A EP3946418A4 (en) 2019-03-26 2020-03-26 COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE
CN202080030026.4A CN113710264A (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular diseases
EA202192607A EA202192607A1 (en) 2019-03-26 2020-03-26 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN EYE DISEASE
IL286625A IL286625A (en) 2019-03-26 2021-09-23 Compositions and methods for treating ocular disease
ZA2021/07235A ZA202107235B (en) 2019-03-26 2021-09-27 Compositions and methods for treating ocular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
US62/824,017 2019-03-26

Publications (1)

Publication Number Publication Date
WO2020198481A1 true WO2020198481A1 (en) 2020-10-01

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/024972 Ceased WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Country Status (12)

Country Link
US (1) US12540171B2 (en)
EP (1) EP3946418A4 (en)
JP (1) JP7650074B2 (en)
KR (1) KR20210146352A (en)
CN (1) CN113710264A (en)
AU (1) AU2020248438A1 (en)
CA (1) CA3134816A1 (en)
EA (1) EA202192607A1 (en)
IL (1) IL286625A (en)
MX (1) MX2021011727A (en)
WO (1) WO2020198481A1 (en)
ZA (1) ZA202107235B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN117126233A (en) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 Peptide-like compound and application thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316950A1 (en) * 2010-12-10 2013-11-28 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
US20140045757A1 (en) * 2005-09-12 2014-02-13 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
WO2018067646A1 (en) * 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
US20180134753A1 (en) * 2013-06-07 2018-05-17 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883150A (en) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 Peptide and nanoparticle formulation with anti-angiogenesis, the generation of antiangiogenic pipe and consumer edema property
US20200179285A1 (en) * 2017-05-08 2020-06-11 The Johns Hopkins University Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045757A1 (en) * 2005-09-12 2014-02-13 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
US20130316950A1 (en) * 2010-12-10 2013-11-28 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
US20180134753A1 (en) * 2013-06-07 2018-05-17 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
WO2018067646A1 (en) * 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAM C MIRANDO, SHEN JIKUI, LIMA RAQUEL, SILVA, CHU ZENNY, SASS NICHOLAS C, LORENC VALERIA E, GREEN JORDAN J, CAMPOCHIARO PETER A: "A collagen IV-derived peptide disrupts a581 integrin and potentiates Ang2/Tie2 signaling", JCI INSIGHT, vol. 4, no. 4, e122043, 21 February 2019 (2019-02-21), pages 1 - 19, XP055744323, DOI: 10.1172/jci.insight.122043 *

Also Published As

Publication number Publication date
KR20210146352A (en) 2021-12-03
AU2020248438A1 (en) 2021-10-28
ZA202107235B (en) 2023-10-25
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
JP7650074B2 (en) 2025-03-24
EA202192607A1 (en) 2022-03-03
US20230054032A1 (en) 2023-02-23
CN113710264A (en) 2021-11-26
IL286625A (en) 2021-12-01
MX2021011727A (en) 2022-01-24
JP2022527276A (en) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
AU2016241499B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN109715189B (en) Humanized monoclonal antibody targeting VE-PTP (HPTP-β)
ES3041647T3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
AU2010336475A1 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2016522250A (en) Use of VEGF antagonists in the treatment of macular edema
ES2886542T3 (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
US12540171B2 (en) Compositions and methods for treating ocular disease
AU2025203373A1 (en) Application Of Fusion Protein In Treating Age-Related Macular Degeneration
US20160129080A1 (en) Treatment of polypoidal chroidal vasculopathy
TW201904610A (en) Non-antibody vegf antagonists for the treatment of neovascular glaucoma
KR20220062279A (en) How to treat eye disease
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
KR20220051791A (en) Composition for preventing or treating macular degeneration comprising Fas signaling-blocking peptide
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2026036282A1 (en) Multispecific fusion proteins targeting angiogenic factors
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2024236190A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
KR20260019535A (en) Complement antibody-drug conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20776493

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3134816

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021557369

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217034683

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020248438

Country of ref document: AU

Date of ref document: 20200326

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020776493

Country of ref document: EP

Effective date: 20211026

WWW Wipo information: withdrawn in national office

Ref document number: 286625

Country of ref document: IL

WWW Wipo information: withdrawn in national office

Ref document number: 780670

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 17442682

Country of ref document: US